Previous 10 | Next 10 |
Adaptimmune Therapeutics (NASDAQ: ADAP ) intends to offer and sell 12.5M American Depositary Shares (ADSs) in a public offering. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, , Stocks on the move, Read more ...
DENVER, Colo., May 29, 2020 - Esports Entertainment Group, (NASDAQ:GMBL), which recently uplisted to the Nasdaq, has been up huge this week, including today’s $1.98 (+36.53%) gain, and currently trading at $7.40. Today’s action appears to be solid follow through on its ...
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this Read more ...
Gainers: Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...
Will You Add these To Your List Of Penny Stocks? No matter if you trade penny stocks or look for ways of investing in penny stocks , there are certainly plenty of choices in the stock market today. But it’s important to remember that there are factors in play that can change your ini...
Sonoma Pharmaceuticals (NASDAQ: SNOA ) +162% on COVID-19 nod in Australia for disinfectant. More news on: Sonoma Pharmaceuticals, Inc., Phio Pharmaceuticals Corp., Adaptimmune Therapeutics plc, Stocks on the move, , Read more ...
Adaptimmune Thereapeutics (NASDAQ: ADAP ) shares soar after data from ADP-A2M4 Phase 1 trial was presented at at the American Society for Clinical Oncology ( OTC:ASCO ) Annual Meeting, showing durability and responses in synovial sarcoma. Data also indicated a new response in a lung ca...
- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned ...
The road to success for most companies, biotechs included, is far from straight forward. Investors want to find those diamonds in the rough whose stock will substantially outperform, not just in the coming months but in the years ahead. One approach for achieving this requires discovering compan...
Adaptimmune Therapeutics plc (ADAP) Q1 2020 Earnings Conference Call May 14, 2020, 08:00 AM ET Company Participants Juli Miller - Director of IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medical Officer Conference Call Participa...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...